Re: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma: Editorial comment

Samir S. Taneja

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Re: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma: Editorial comment'. Together they form a unique fingerprint.